News: Acorda Therapeutics Inc (ACOR.O)
32.67USD
24 May 2013
$0.44 (+1.37%)
$32.23
$32.13
$32.77
$31.78
269,290
453,425
$40.87
$21.26
Thu, Dec 20 2012
Potentially game changing data awaits Acorda in 2013
NEW YORK - Acorda Therapeutics Inc Chief Executive Ron Cohen is already looking to spring, when data on a new use for its lone product could spur renewed investor interest and provide funding to enable his company to develop even more therapies.
Press Releases
- CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
- Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine
- Acorda Therapeutics to Present at the UBS Global Healthcare Conference
- Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in Stroke
- Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
- Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive Year
- Acorda Therapeutics Reports First Quarter 2013 Financial Results
- Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013
- Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
